Last week we hosted the inaugural Cell Therapy Manufacturing & Gene Therapy Digital Week. An agenda of seven live webinars covered a range of the hottest topics in the industry, led by leading life science thought leaders from GSK, ISCT, Cell Medica and many more.
Every session is now available to watch on-demand at the links below. If you registered for the live event you can watch the on-demand sessions with the same login details, or if you haven’t yet registered it only takes 10 seconds.
- Making cell therapy process changes: Why, how, and when? – Greg Russotti, Vice President, Technical Operations, Celgene Cellular Therapeutics, USA
- The CAP®GT Expression System: Fully Scalable Production of Gene Therapy Vectors in a Human Suspension Cell Line – Hartmut Tintrup, Director Business Development, CEVEC Pharmaceuticals GmbH
- Developing a stringent, commercially viable manufacturing strategy – Anticipating your end point – Alain Pralong, Senior Vice President, Manufacturing Operations, Cell Medica, UK
- Planning for success – Pre-clinical and phase I trial considerations to prevent failure at marketing authorisation approval – Professor Mark Lowdell, ISCT VP Europe and Professor of Cell & Tissue Therapy, UCL, United Kingdom
- Clinical development of Vvax001, a Semliki forest virus-based cancer vaccine for treatment of HPV-related (pre)-malignancies – Janneke Meulenberg, CEO, ViciniVax, The Netherlands
- Cell & Gene Therapies: From Discovery Research to Manufacturing and Commercialisation – Dr Takis Athanasopoulos, Head of Transgene Delivery, Cell & Gene Therapy Discovery Research Platform Technology & Sciences, GSK, United Kingdom
- A Closer Look at Orphan ATMP Development, Incentives and Similarity – Alex Bloom, Director, Regulatory Affairs (EU), Cell Medica, UK
Over the course of the week there were dozens of questions and hundreds of responses to polls from live audiences.
GSK’s Dr Takis Athanasopoulos’s session acted as a state-of-the-industry exploration of taking cell and gene therapies from discovery to manufacturing and commercialisation. A number of polls asked some of the burning issues in the industry – look out for a post next week devoted to the results.
A live Q&A session with each speaker followed the presentations and over 50 questions were asked, with the following offering a flavour of what was covered:
- What are the main limits today in the application of cell therapy as a standard of care?
- Do you see a shift from the traditional large scale bioreactors to smaller scale bioreactors as therapies keep evolving?
- What is the best way to get over the capital costs associated with process closure?
- How much money should one expect to allocate to the regulatory approval process for developing an orphan drug?
- What does the next-generation process look like for vector and cell manufacturing?
- What single-use technology does not exist today that would help cell and gene therapies?
The BioProcess International Digital Week is taking place on May 1-4, 2017. Register here.